Last 23 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.17 | 3.38 | 4.25 | 5.77 | 5.97 | 10.08 | 11.57 | 15.88 | 17.85 | 14.78 | 14.15 | 12.16 | 11.29 | 12.06 | 13.11 | 19.55 | 22.74 | 21.70 | 27.02 | 26.85 | 46.63 |
| — | -66.5% | -63.2% | -63.6% | -66.6% | -31.8% | -18.3% | +30.6% | +58.1% | +22.6% | +7.9% | -37.8% | -50.4% | -44.4% | -51.5% | -27.2% | -51.2% | — | — | — | — | |
| P/B Ratio | 2.61 | 3.75 | 4.07 | 4.82 | 5.23 | 8.28 | 8.22 | 10.78 | 17.28 | 12.53 | 9.55 | 7.55 | 5.29 | 10.24 | 7.39 | 9.44 | 8.38 | 6.06 | 6.07 | 4.08 | 5.71 |
| — | -54.7% | -50.6% | -55.3% | -69.7% | -33.9% | -13.9% | +42.7% | +226.3% | +22.3% | +29.1% | -20.0% | -36.8% | +69.0% | +21.8% | +131.5% | +46.9% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.7% | 66.0% | 64.9% | 60.6% | 62.9% | 63.3% | 63.9% | 64.0% | 63.2% | 59.0% | 56.2% | 48.8% | 53.8% | 55.7% | 51.2% | 44.9% | 50.3% | 50.8% | 54.2% | 44.5% | 48.9% |
| — | +4.2% | +1.6% | -5.3% | -0.6% | +7.4% | +13.6% | +31.2% | +17.6% | +6.0% | +9.8% | +8.6% | +6.9% | +9.5% | -5.5% | +0.8% | +2.8% | +20.3% | +10.5% | +205.3% | — | |
| Operating Margin | -33.7% | -29.0% | -39.2% | -40.6% | -27.8% | -28.0% | -39.7% | -28.9% | -38.4% | -50.3% | -62.1% | -67.8% | -73.0% | -77.4% | -116.3% | -105.3% | -108.6% | -107.1% | -110.6% | -166.0% | -147.6% |
| — | -3.4% | +1.1% | -40.7% | +27.6% | +44.3% | +36.1% | +57.4% | +47.3% | +35.0% | +46.6% | +35.6% | +32.8% | +27.7% | -5.1% | +36.6% | +26.4% | +31.2% | +29.9% | +59.5% | — | |
| Net Margin | -31.0% | -28.4% | -38.1% | -39.1% | -25.7% | -24.7% | -35.8% | -27.6% | -35.9% | -48.0% | -58.3% | -63.1% | -70.1% | -76.4% | -116.7% | -118.5% | -111.1% | -114.9% | -121.0% | -181.0% | -162.7% |
| — | -15.0% | -6.4% | -41.4% | +28.5% | +48.5% | +38.6% | +56.2% | +48.8% | +37.1% | +50.1% | +46.7% | +36.9% | +33.5% | +3.6% | +34.5% | +31.7% | +33.2% | +32.1% | +61.8% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.9% | -7.8% | -8.9% | -8.0% | -5.6% | -5.1% | -6.3% | -5.9% | -8.5% | -9.9% | -9.5% | -9.5% | -10.8% | -15.4% | -15.4% | -13.5% | -9.8% | -7.8% | -6.6% | -6.7% | -36.6% |
| — | -54.6% | -41.9% | -36.5% | +34.3% | +49.1% | +34.4% | +38.2% | +21.3% | +35.4% | +38.1% | +29.7% | -10.0% | -97.1% | -132.8% | -102.3% | +73.2% | — | +68.6% | — | — | |
| ROA | -18.3% | -5.6% | -6.4% | -5.9% | -4.2% | -3.8% | -4.7% | -4.2% | -5.6% | -6.8% | -6.6% | -6.7% | -7.1% | -9.1% | -9.6% | -8.9% | -7.1% | -6.1% | -5.2% | -5.3% | -5.2% |
| — | -46.6% | -35.4% | -41.0% | +25.4% | +44.0% | +28.7% | +37.7% | +21.1% | +25.5% | +31.3% | +25.1% | +0.3% | -49.5% | -83.7% | -66.9% | -36.9% | +20.6% | — | +56.1% | — | |
| ROIC | -50.8% | -11.1% | -14.5% | -14.4% | -10.6% | -10.6% | -13.7% | -10.8% | -13.8% | -16.9% | -18.6% | -22.9% | -21.7% | -24.4% | -34.6% | -37.6% | -46.6% | -59.2% | -60.1% | -74.2% | — |
| — | -5.3% | -6.0% | -33.6% | +23.0% | +37.4% | +26.7% | +52.8% | +36.3% | +30.8% | +46.1% | +39.2% | +53.6% | +58.8% | +42.5% | +49.3% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.23 | 0.22 | 0.21 | 0.21 | 0.21 | 0.21 | 0.20 | 0.33 | 0.32 | 0.31 | 0.28 | 0.27 | 0.52 | 0.46 | 0.39 | 0.35 | 0.22 | 0.21 | 0.20 | 0.19 |
| — | +10.8% | +9.4% | +7.5% | -37.9% | -36.1% | -33.5% | -29.3% | +25.5% | -37.9% | -33.3% | -28.1% | -23.2% | +131.2% | +116.9% | +93.7% | +80.8% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.85 | 6.55 | 6.73 | 6.85 | 8.43 | 9.20 | 8.94 | 9.07 | 6.02 | 7.51 | 8.52 | 7.63 | 8.91 | 6.40 | 7.56 | 7.73 | 10.56 | 16.01 | 20.87 | 20.08 | 23.94 |
| — | -28.9% | -24.7% | -24.5% | +40.0% | +22.5% | +4.9% | +18.8% | -32.5% | +17.4% | +12.7% | -1.2% | -15.6% | -60.0% | -63.8% | -61.5% | -55.9% | +24.8% | — | +164.6% | — | |
| Quick Ratio | 5.77 | 5.35 | 5.51 | 5.77 | 7.19 | 7.86 | 7.74 | 8.01 | 5.07 | 6.49 | 7.44 | 6.77 | 7.89 | 5.21 | 6.36 | 6.92 | 9.74 | 15.27 | 19.98 | 19.27 | 23.19 |
| — | -31.9% | -28.9% | -28.0% | +41.7% | +21.1% | +4.0% | +18.4% | -35.7% | +24.5% | +17.0% | -2.2% | -19.0% | -65.9% | -68.2% | -64.1% | -58.0% | +26.7% | — | +172.4% | — | |
| Interest Coverage | -25.60 | -30.79 | -37.68 | -32.17 | -22.30 | -20.87 | -27.21 | -18.46 | -17.40 | -23.88 | -23.84 | -23.45 | -23.16 | -25.20 | -31.15 | -31.53 | -14.54 | -12.31 | -11.05 | -11.74 | -8.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRCT stock.
PROCEPT BioRobotics Corporation's current P/E is -10.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
PROCEPT BioRobotics Corporation's current operating margin is -33.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PROCEPT BioRobotics Corporation's business trajectory between earnings reports.